



Drug Utilization Review Board Meeting Minutes January 14th, 2025

DRAFT pending approval at the next meeting

DUR Board Members in attendance: Marin Broucek, M.D., Matt Titchener R.P.- in person.
Charlie Moore, R.P., Dave Randolph R.P. - virtual

Nebraska Medicaid & LTC attendees in person: Lee Stutzman, R.P., Pharmacy Director; Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Shannon Nelson, R.P., Molina Healthcare of Nebraska; Shaleigh Hammons, Account executive, Prime Therapeutics, Nikia Bennette-Carter, R.P. Pharmacist, Prime Therapeutics - virtual.

Public visitors in attendance in person: Camille Kerr, Regeneron. Multiple persons virtually.

I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30pm. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. The open meetings act was available.

II. Conflict of Interest or changes

No changes in conflict of interest were declared.

III. Agenda approval

The agenda was unanimously approved.

IV. Approval of Minutes from DUR Board, November 14th, 2024 meeting

The minutes were unanimously approved.

V. Update on Recommendations from previous meeting - None

VI. Retrospective DUR

A. Old Business –

a. Gabapentin and Pregabalin Utilization

- i. Spencer Moore presented data on the utilization of gabapentin and pregabalin, noting that usage levels were normal with minimal concomitant use. The board determined no further intervention was necessary.

B. New Business –

a. Stimulant use

- i. Spencer Moore also presented data on stimulant utilization within the Nebraska Medicaid population, focusing on individuals aged 3 to 18. Charlie Moore suggested expanding the review to include the adult population. The board recommended analyzing stimulant utilization segmented by age bands from 20 years through 80+ years. A motion was made to provide this data at the next meeting.

Vote: Titchener-yes, Dr Broucek-yes, C. Moore-yes, Randolph-absent

b. Substance Use Disorder and Related Treatments

- i. Lee Stutzman led a discussion on Substance Use Disorder, presenting data that showed Nebraska ranks 49th in reported opioid deaths per capita. However, there has been an increase in emergency service utilization related to suspected opioid overdoses. Titchener suggested issuing an educational letter for practitioners and pharmacists to encourage collaboration. A vote was taken to partner with state medical and pharmacy associations to create a one-page document highlighting guidance on SUD treatment.

Vote: Dr Broucek-yes, C. Moore-yes, Titchener-yes, Randolph-yes

VII. Prospective DUR

A. Old Business – None

B. New Business –

- a. Dianne Garside provided updates on the Immunomodulators PA form.

VIII. Special Requests from the Department

A. Project requests for the coming year

- a. Stutzman informed the board that increased monitoring of antipsychotic medications will be required in 2026, in addition to current psychotropic monitoring requirements under the SUPPORT Act.
- b. State asked Board for discussion topics for the coming year
 - i. Broucek recommended a review of high-cost medications, excluding chemotherapy. The state agreed to provide data on the top 10 drugs by cost.
 - ii. Randolph recommended conducting a review of non-adherence to HIV and TB medications, defining non-adherence as a refill gap of 40 days or more.
 - iii. Titchener proposed a review of the concurrent use of GLP-1 and DDP-4 medications.
 - iv. Broucek inquired about the state's monitoring of TB medication refills. Stutzman will follow up with public health partners and report back to the Board.
 - v. Broucek asked about looking at Naltrexone or SUD treatments with benzodiazepines.

IX. Future Meeting Dates

- A. Stutzman announced the next DUR Board meeting dates for 2025 will be May 13th, September 9th, and October 28th with the option to add 2 additional meetings, if needed.

X. Concerns and Comments from Board Members

- A. Charlie Moore raised concerns about the reimbursement of MAC pricing.

XI. Concerns and Comments from DUR Director:

- A. Stutzman announced the appointment of Drew Gonshorowski introduced as the new State Medicaid Director.

XII. Concerns and Comments from DHHS State Representatives-None

XIII. Concerns and Comments from MCO Directors-None

XIV. Concerns and Comments from Public Attendees-None

XV. Adjournment

- A. The meeting adjourned at 7:30 PM, approved unanimously.